ATB-429, a H2S-releasing derivative of Mesalamine (HY-15027), demonstrates significant anti-nociceptive and anti-inflammatory effects in models of irritable bowel syndrome (IBS). By releasing H2S, ATB-429 modulates colorectal distension-induced hypersensitivity in both healthy and postcolitic rats. It attenuates abdominal withdrawal responses and suppresses spinal c-Fos mRNA expression, indicating its potential to alleviate pain associated with gastrointestinal inflammation. ATB-429 down-regulates colonic COX-2 and IL-1beta mRNA expression, effects not observed with mesalamine alone. The mechanism involves ATP-sensitive K+ (KATP) channels, as evidenced by reversal of ATB-429s effects with Glibenclamide (HY-15206)[1].
Molekulargewicht:
361.46
CAS Nummer:
[915282-45-0]
Formel:
C16H11NO3S3
Target-Kategorie:
Endogenous Metabolite
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
